Stay updated on Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial

Sign up to get notified when there's something new on the Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The page’s UI/version label was updated from “Revision: v3.5.2” to “Revision: v3.5.3.” This reflects a change in the site’s revision/version rather than a modification to the underlying clinical trial record.
    Difference
    0.1%
    Check dated 2026-04-24T05:51:20.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    Added revision: v3.5.2; removed revision: v3.5.0.
    Difference
    0.1%
    Check dated 2026-04-17T02:21:35.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    Added new sections for Contacts/Locations and Study Status in the record history to reflect updated metadata for the trial.
    Difference
    0.4%
    Check dated 2026-04-09T20:56:51.000Z thumbnail image
  4. Check
    38 days ago
    Change Detected
    Summary
    Revision v3.5.0 was added to the history and Revision v3.4.3 was removed.
    Difference
    0.1%
    Check dated 2026-03-18T21:16:12.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    A new revision entry (v3.4.3) was added to the history and the previous revision (v3.4.2) was removed.
    Difference
    0.1%
    Check dated 2026-03-11T17:56:16.000Z thumbnail image
  6. Check
    73 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 to the page. The government funding status notice and the prior Revision: v3.4.1 were removed.
    Difference
    0.6%
    Check dated 2026-02-11T06:16:46.000Z thumbnail image

Stay in the know with updates to Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial page.